Omeros' stock surged over 150% after licensing zaltenibart to Novo Nordisk for $240M upfront, plus milestones and royalties.
Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.
Fortress Power has released its new energy storage system, the eBoost. Sixteen of the 16-kWh units can be connected in ...
WYFF News 4 on MSN
South Carolina public defender: Shutdown exacerbates ongoing funding crisis among federal attorneys
Federal public defenders, private attorneys and supplemental employees will begin working without pay on Monday.
A new twist on a classic material could advance quantum computing and make modern data centers more energy efficient, ...
Newspoint on MSN
Same-Day cheque Clearing: Cheque will be cleared within 3 hours from this day, a major relief for customers with RBI's new system.
In fact, the Reserve Bank is implementing cheque clearance in two phases. The first phase, which began on October 4th, will ...
The University of the Free State and student leaders have reached an agreement to phase out provisional registration over two ...
Microsoft is encouraging people to talk to their laptops with new AI updates to Windows 11, but millions of computer users ...
A couple say they have cut their energy bills by hundreds of pounds thanks to solar panels, and they hope to recoup the cost ...
Sea drones or USVs have been the stars in Ukraine’s war against Russia. These are uncrewed, remotely controlled vessels that carry explosives and can be guided towards ships. With its virtually ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback